Impax Laboratories Stock Price, News & Analysis (NASDAQ:IPXL)

$20.30 -0.20 (-0.98 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$20.30
Today's Range$20.20 - $21.45
52-Week Range$7.75 - $25.70
Volume1.02 million shs
Average Volume958,517 shs
Market Capitalization$1.51 billion
P/E Ratio-3.25
Dividend YieldN/A
Beta1.11

About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Receive IPXL News and Ratings via Email

Sign-up to receive the latest news and ratings for IPXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:IPXL
CUSIP45256B10
Phone510-240-6000

Debt

Debt-to-Equity Ratio1.59%
Current Ratio1.81%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E Ratio-3.248
Forward P/E Ratio32.22
P/E Growth1.01

Sales & Book Value

Annual Sales$824.43 million
Price / Sales1.82
Cash Flow$2.32 per share
Price / Cash8.76
Book Value$8.45 per share
Price / Book2.40

Profitability

Trailing EPS($6.25)
Net Income$-472,030,000.00
Net Margins-23.92%
Return on Equity-39.31%
Return on Assets-11.82%

Miscellaneous

Employees1,495
Outstanding Shares74,050,000

Impax Laboratories (NASDAQ:IPXL) Frequently Asked Questions

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories Inc (NASDAQ:IPXL) released its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to analysts' expectations of $208.38 million. Impax Laboratories had a negative net margin of 23.92% and a negative return on equity of 39.31%. The firm's quarterly revenue was down 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.37 earnings per share. View Impax Laboratories' Earnings History.

When will Impax Laboratories make its next earnings announcement?

Impax Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Impax Laboratories.

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2018?

14 brokerages have issued twelve-month target prices for Impax Laboratories' shares. Their forecasts range from $10.00 to $35.00. On average, they expect Impax Laboratories' share price to reach $20.29 in the next year. View Analyst Ratings for Impax Laboratories.

What are Wall Street analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

  • 1. According to Zacks Investment Research, "Impax's epinephrine auto-injector sales have picked up and the company has 18 ANDAs pending FDA approval. Impax’s generics pipeline should be able to take advantage of the upcoming patent expirations amid competitive and pricing pressure, which is expected to persist through 2017. Meanwhile, Impax is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. However, the company’s manufacturing facilities have been hampered by quality control issues since 2011, which delayed Rytary’s approval. Impax’s shares have outperformed the industry in the past one year. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters." (1/15/2018)
  • 2. Cantor Fitzgerald analysts commented, "IPXL announced this morning that Robert Stewart will be joining the company as CEO, effective January 25, 2018." (12/15/2017)

Are investors shorting Impax Laboratories?

Impax Laboratories saw a increase in short interest in January. As of January 31st, there was short interest totalling 12,440,931 shares, an increase of 8.8% from the January 12th total of 11,436,797 shares. Based on an average daily volume of 1,023,870 shares, the days-to-cover ratio is presently 12.2 days. Approximately 18.0% of the company's stock are short sold.

Who are some of Impax Laboratories' key competitors?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:

  • Robert L. Burr, Independent Chairman of the Board
  • Paul M. Bisaro, President, Chief Executive Officer, Director
  • Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
  • Douglas S Boothe, President - Generics Division
  • Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
  • Robert A. Stewart, President of Amneal
  • Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
  • Jeffrey D. Nornhold, Senior Vice President - Technical Operations
  • J. Kevin Buchi, Director
  • Janet S Vergis, Director

Who owns Impax Laboratories stock?

Impax Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (9.89%), TCW Group Inc. (2.68%), GW&K Investment Management LLC (2.51%), Goldman Sachs Group Inc. (2.19%), Fisher Asset Management LLC (2.00%) and Frontier Capital Management Co. LLC (1.98%). Company insiders that own Impax Laboratories stock include Leslie Z Benet and Michael Nestor. View Institutional Ownership Trends for Impax Laboratories.

Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Goldman Sachs Group Inc., Millennium Management LLC, Frontier Capital Management Co. LLC, Two Sigma Advisers LP, Alliancebernstein L.P., Congress Asset Management Co. MA and Dupont Capital Management Corp. View Insider Buying and Selling for Impax Laboratories.

Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?

Impax Laboratories' stock was bought by a variety of institutional investors in the last quarter, including TCW Group Inc., GW&K Investment Management LLC, Maverick Capital Ltd., Renaissance Technologies LLC, WINTON GROUP Ltd, Element Capital Management LLC, Hussman Strategic Advisors Inc. and Arizona State Retirement System. View Insider Buying and Selling for Impax Laboratories.

How do I buy Impax Laboratories stock?

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of Impax Laboratories stock can currently be purchased for approximately $20.30.

How big of a company is Impax Laboratories?

Impax Laboratories has a market capitalization of $1.51 billion and generates $824.43 million in revenue each year. The specialty pharmaceutical company earns $-472,030,000.00 in net income (profit) each year or ($6.25) on an earnings per share basis. Impax Laboratories employs 1,495 workers across the globe.

How can I contact Impax Laboratories?

Impax Laboratories' mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company can be reached via phone at 510-240-6000 or via email at [email protected]


MarketBeat Community Rating for Impax Laboratories (IPXL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  464 (Vote Underperform)
Total Votes:  778
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Impax Laboratories (NASDAQ:IPXL) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.362.362.382.15
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.29$20.29$20.31$18.77
Price Target Upside: 0.07% downside15.26% upside10.97% upside13.41% upside

Impax Laboratories (NASDAQ:IPXL) Consensus Price Target History

Price Target History for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ:IPXL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018Canaccord GenuitySet Price TargetHold$19.00LowView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$22.00MediumView Rating Details
12/15/2017Cantor FitzgeraldSet Price TargetBuy$35.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$18.00HighView Rating Details
11/10/2017CowenReiterated RatingHold$16.00N/AView Rating Details
10/17/2017Royal Bank of CanadaSet Price TargetHold$17.00N/AView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageNeutral$20.00HighView Rating Details
9/23/2017BTIG ResearchReiterated RatingBuy$20.00 -> $27.00LowView Rating Details
9/19/2017Deutsche BankReiterated RatingBuy$23.00LowView Rating Details
9/19/2017CitigroupBoost Price TargetBuy$23.00LowView Rating Details
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$17.00LowView Rating Details
6/23/2017BMO Capital MarketsReiterated RatingHold$16.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingNeutral$21.00HighView Rating Details
3/8/2017Susquehanna BancsharesDowngradePositive -> Neutral$18.00 -> $10.00LowView Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00N/AView Rating Details
11/7/2016Bank of AmericaDowngradeNeutral -> Underperform$19.00N/AView Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00N/AView Rating Details
6/1/2016JPMorgan Chase & Co.Initiated CoverageNeutral$47.00N/AView Rating Details
3/2/2016NomuraReiterated RatingHoldN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Impax Laboratories (NASDAQ:IPXL) Earnings History and Estimates Chart

Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ IPXL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$0.12N/AView Earnings Details
11/9/2017Q3 2017$0.20$0.23$208.38 million$206.40 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.14$0.18$195.62 million$202.08 millionViewListenView Earnings Details
5/10/2017Q1 2017$0.12$0.11$193.17 million$184.40 millionViewN/AView Earnings Details
3/1/2017Q416$0.16$0.16$219.54 million$198.40 millionViewListenView Earnings Details
11/9/2016Q316$0.40$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.11$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.39$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.13$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
11/2/2010Q3 2010$0.26$0.20ViewN/AView Earnings Details
8/3/2010Q2 2010$0.51$0.48ViewN/AView Earnings Details
5/4/2010Q1 2010$0.51$2.06ViewN/AView Earnings Details
2/25/2010Q4 2009$0.14$0.69ViewN/AView Earnings Details
11/3/2009Q3 2009$0.04$0.11ViewN/AView Earnings Details
8/4/2009Q2 2009$0.03$0.05ViewN/AView Earnings Details
5/5/2009Q1 2009($0.07)$0.05ViewN/AView Earnings Details
2/26/2009Q4 2008$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Impax Laboratories (NASDAQ:IPXL) Earnings Estimates

2018 EPS Consensus Estimate: $1.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.28$0.28$0.28
Q2 20181$0.35$0.35$0.35
Q3 20181$0.39$0.39$0.39
Q4 20181$0.39$0.39$0.39
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Impax Laboratories (NASDAQ:IPXL)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Impax Laboratories (NASDAQ IPXL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 99.05%
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories (NASDAQ IPXL) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/31/2017Michael NestorInsiderSell1,130$15.00$16,950.00106,943View SEC Filing  
5/17/2017Michael NestorInsiderSell857$16.48$14,123.36108,073View SEC Filing  
5/12/2017Michael NestorInsiderSell700$17.11$11,977.00115,168View SEC Filing  
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.5240,225View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.1073,588View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00111,833View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.008,200View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.0981,045View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.6939,787View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.768,200View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00409,568View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00459,568View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.0011,266View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.148,366View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.009,699View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08458,568View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.009,699View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.0043,825View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.0046,825View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.0048,325View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.0049,825View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.0051,325View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Impax Laboratories (NASDAQ IPXL) News Headlines

Source:
DateHeadline
Impax Laboratories (IPXL) Given a $19.00 Price Target by Canaccord Genuity AnalystsImpax Laboratories (IPXL) Given a $19.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - February 23 at 7:24 PM
Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®
finance.yahoo.com - February 21 at 8:19 AM
New Research Coverage Highlights Timken Steel, National Health Investors, Donaldson, Array BioPharma, Impax Laboratories, and Baxter International — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Timken Steel, National Health Investors, Donaldson, Array BioPharma, Impax Laboratories, and Baxter International — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - February 21 at 8:19 AM
Impax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release TabletsImpax Announces the Launch of an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
finance.yahoo.com - February 20 at 5:48 PM
Impax Laboratories (IPXL) Set to Announce Quarterly Earnings on TuesdayImpax Laboratories (IPXL) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
BidaskClub Lowers Impax Laboratories (IPXL) to SellBidaskClub Lowers Impax Laboratories (IPXL) to Sell
www.americanbankingnews.com - February 17 at 2:10 PM
Free Research Reports on These Drug Makers Stocks -- Impax Labs, Merck ...Free Research Reports on These Drug Makers Stocks -- Impax Labs, Merck ...
www.prnewswire.com - February 16 at 5:19 PM
Impax Laboratories Inc (IPXL) Given Average Recommendation of "Hold" by AnalystsImpax Laboratories Inc (IPXL) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 13 at 9:22 AM
Impax Laboratories (IPXL) Upgraded at BidaskClubImpax Laboratories (IPXL) Upgraded at BidaskClub
www.americanbankingnews.com - February 11 at 9:42 PM
Andrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial OperationsAndrew S. Boyer Joins Amneal Pharmaceuticals as Executive Vice President, Commercial Operations
www.prnewswire.com - February 6 at 7:43 AM
Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta®
finance.yahoo.com - February 5 at 9:25 AM
Read This Before Buying Impax Asset Management Group plc (LON:IPX) For Its Upcoming £0.02 DividendRead This Before Buying Impax Asset Management Group plc (LON:IPX) For Its Upcoming £0.02 Dividend
finance.yahoo.com - February 4 at 3:49 PM
Impax Laboratories (IPXL) Cut to "Sell" at BidaskClubImpax Laboratories (IPXL) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - February 3 at 7:40 PM
Amneal Introduces Isotretinoin Capsules, USPAmneal Introduces Isotretinoin Capsules, USP
www.bizjournals.com - February 1 at 3:41 PM
CorePharma, LLC Acquired by Investor GroupCorePharma, LLC Acquired by Investor Group
finance.yahoo.com - January 31 at 9:28 AM
Q1 2018 EPS Estimates for Impax Laboratories Inc Lifted by Analyst (IPXL)Q1 2018 EPS Estimates for Impax Laboratories Inc Lifted by Analyst (IPXL)
www.americanbankingnews.com - January 29 at 2:18 AM
Impax Laboratories (IPXL) Upgraded to Hold at BidaskClubImpax Laboratories (IPXL) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - January 27 at 11:18 AM
Blog Exposure - FDA Granted Final Approval to a Generic Version of Perrigo’s Estrace CreamBlog Exposure - FDA Granted Final Approval to a Generic Version of Perrigo’s Estrace Cream
finance.yahoo.com - January 26 at 8:59 AM
Did Impax Asset Management Group plc’s (LON:IPX) Recent Earnings Growth Beat The Trend?Did Impax Asset Management Group plc’s (LON:IPX) Recent Earnings Growth Beat The Trend?
finance.yahoo.com - January 24 at 8:05 AM
Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® CreamPerrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream
finance.yahoo.com - January 24 at 8:05 AM
Impax Laboratories Inc (IPXL) Expected to Post Quarterly Sales of $196.43 MillionImpax Laboratories Inc (IPXL) Expected to Post Quarterly Sales of $196.43 Million
www.americanbankingnews.com - January 24 at 4:48 AM
Zacks: Brokerages Anticipate Impax Laboratories Inc (IPXL) Will Announce Earnings of $0.12 Per ShareZacks: Brokerages Anticipate Impax Laboratories Inc (IPXL) Will Announce Earnings of $0.12 Per Share
www.americanbankingnews.com - January 22 at 1:26 PM
Impax Laboratories Inc (IPXL) Receives Average Rating of "Hold" from BrokeragesImpax Laboratories Inc (IPXL) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 10:02 AM
Commit To Buy Impax Laboratories At $14, Earn 13.2% Annualized Using OptionsCommit To Buy Impax Laboratories At $14, Earn 13.2% Annualized Using Options
www.nasdaq.com - January 18 at 2:59 PM
Impax Laboratories (IPXL) Upgraded at Zacks Investment ResearchImpax Laboratories (IPXL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 15 at 4:28 PM
Impax Laboratories (IPXL) vs. Sagent Pharmaceuticals (SGNT) Financial AnalysisImpax Laboratories (IPXL) vs. Sagent Pharmaceuticals (SGNT) Financial Analysis
www.americanbankingnews.com - January 8 at 12:04 PM
Zacks: Analysts Anticipate Impax Laboratories Inc (IPXL) Will Announce Quarterly Sales of $196.43 MillionZacks: Analysts Anticipate Impax Laboratories Inc (IPXL) Will Announce Quarterly Sales of $196.43 Million
www.americanbankingnews.com - January 7 at 9:10 AM
Impax Laboratories Inc (IPXL) Expected to Post Earnings of $0.12 Per ShareImpax Laboratories Inc (IPXL) Expected to Post Earnings of $0.12 Per Share
www.americanbankingnews.com - January 5 at 1:38 PM
Leerink Swann Comments on Impax Laboratories Incs FY2017 Earnings (IPXL)Leerink Swann Comments on Impax Laboratories Inc's FY2017 Earnings (IPXL)
www.americanbankingnews.com - January 5 at 8:14 AM
Impax Laboratories Inc Forecasted to Earn Q1 2018 Earnings of $0.19 Per Share (IPXL)Impax Laboratories Inc Forecasted to Earn Q1 2018 Earnings of $0.19 Per Share (IPXL)
www.americanbankingnews.com - January 4 at 11:10 AM
Head to Head Contrast: Impax Laboratories (IPXL) & Concordia International (CXRX)Head to Head Contrast: Impax Laboratories (IPXL) & Concordia International (CXRX)
www.americanbankingnews.com - January 4 at 9:56 AM
Impax Laboratories (IPXL) Now Covered by Analysts at Leerink SwannImpax Laboratories (IPXL) Now Covered by Analysts at Leerink Swann
www.americanbankingnews.com - January 2 at 5:18 PM
Impax Laboratories (IPXL) Stock Rating Lowered by Zacks Investment ResearchImpax Laboratories (IPXL) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:44 PM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- TherapeuticsMD, Impax Laboratories, GlaxoSmithKline, and AstraZenecaQuotidian Technical Highlights on Selected Drug Makers Stocks -- TherapeuticsMD, Impax Laboratories, GlaxoSmithKline, and AstraZeneca
www.prnewswire.com - December 29 at 7:52 AM
Impax Laboratories Inc (IPXL) Receives Consensus Rating of "Hold" from AnalystsImpax Laboratories Inc (IPXL) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 25 at 10:06 AM
 Analysts Anticipate Impax Laboratories Inc (IPXL) Will Post Quarterly Sales of $198.42 Million Analysts Anticipate Impax Laboratories Inc (IPXL) Will Post Quarterly Sales of $198.42 Million
www.americanbankingnews.com - December 22 at 8:54 PM
Impax Laboratories (IPXL) to Sell Taiwan Manufacturing Facility - StreetInsider.comImpax Laboratories (IPXL) to Sell Taiwan Manufacturing Facility - StreetInsider.com
www.streetinsider.com - December 19 at 3:39 PM
Impax Laboratories (IPXL) Given "Hold" Rating at Canaccord GenuityImpax Laboratories (IPXL) Given "Hold" Rating at Canaccord Genuity
www.americanbankingnews.com - December 18 at 8:26 PM
Form 425 IMPAX LABORATORIES INC Filed by: IMPAX LABORATORIES INC - StreetInsider.comForm 425 IMPAX LABORATORIES INC Filed by: IMPAX LABORATORIES INC - StreetInsider.com
www.streetinsider.com - December 18 at 3:38 PM
Impax Laboratories (IPXL) versus AzurRx BioPharma (AZRX) Financial AnalysisImpax Laboratories (IPXL) versus AzurRx BioPharma (AZRX) Financial Analysis
www.americanbankingnews.com - December 18 at 11:50 AM
Impax Laboratories (IPXL) Earns Neutral Rating from Analysts at GuggenheimImpax Laboratories (IPXL) Earns Neutral Rating from Analysts at Guggenheim
www.americanbankingnews.com - December 17 at 9:26 PM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Impax Laboratories, Inc. - IPXL - PR Newswire (press release)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Impax Laboratories, Inc. - IPXL - PR Newswire (press release)
www.prnewswire.com - December 16 at 11:16 AM
ETFs with exposure to Impax Laboratories, Inc. : December 15, 2017ETFs with exposure to Impax Laboratories, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 3:44 PM
Cantor Fitzgerald Analysts Give Impax Laboratories (IPXL) a $35.00 Price TargetCantor Fitzgerald Analysts Give Impax Laboratories (IPXL) a $35.00 Price Target
www.americanbankingnews.com - December 15 at 3:38 PM
Impax Laboratories (IPXL) Announces Tentative FDA Approval of Generic Coreg CR Extended-Release Capsules - StreetInsider.comImpax Laboratories (IPXL) Announces Tentative FDA Approval of Generic Coreg CR Extended-Release Capsules - StreetInsider.com
www.streetinsider.com - December 10 at 3:43 PM
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Shareholders to Contact the Firm for Additional ...INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Shareholders to Contact the Firm for Additional ...
www.businesswire.com - December 8 at 3:38 PM
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Shareholders to Contact the Firm for Additional InformationINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
finance.yahoo.com - December 8 at 3:38 PM
Impax Receives Tentative FDA Approval of Generic Coreg CR® (Carvedilol Phosphate) Extended-Release CapsulesImpax Receives Tentative FDA Approval of Generic Coreg CR® (Carvedilol Phosphate) Extended-Release Capsules
www.prnewswire.com - December 8 at 8:10 AM
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional ...SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional ...
www.businesswire.com - December 6 at 8:47 AM
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional InformationSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Impax Laboratories, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - December 5 at 6:02 PM

SEC Filings

Impax Laboratories (NASDAQ:IPXL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Impax Laboratories (NASDAQ:IPXL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Impax Laboratories (NASDAQ IPXL) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.